|
Prescription Drug Search
Strengths available for Angiomax vial:
Browse Alphabetically:
A
·
B
·
C
·
D
·
E
·
F
·
G
·
H
·
I
·
J
·
K
·
L
·
M
·
N
O
·
P
·
Q
·
R
·
S
·
T
·
U
·
V
·
W
·
X
·
Y
·
Z
·
#
Information about MyGlobalPharmacy.com
List of countries where we can ship Angiomax:
- Algeria
- Argentina
- Armenia
- Aruba
- Australia
- Austria
- Bahamas
- Bahrain
- Bermuda
- China
- Cuba
- Cyprus
- Dominican Republic
- Ecuador
- El Salvador
- Estonia
- Georgia
- Germany
- Greece
- Guatemala
- Hong Kong
- Hungary
- India
- Iran
- Italy
- Jordan
- Kuwait
- Lebanon
- Malta
- Monaco
- Morocco
- New Zealand
- Philippines
- Portugal
- Qatar
- Romania
- Saint Lucia
- Slovakia
- Taiwan
- United Kingdom, UK
Latest news releases on Angiomax:
Shares of Medicines Co Receive a Boost, Up 2.5% - Financial News Network Online
The Medicines Company develops products that improve specialized care. The Company markets Angiomax, an anticoagulant approved in the United States and other countries for use in patients undergoing coronary angioplasty procedures. In the past 52 weeks ...
MDCO Beats, Ties With AstraZeneca - Daily Markets
Revenues, up 12.9% at $126.6 million, were above the Zacks Consensus Estimate of $124 million. The Quarter in Detail Angiomax US sales increased 10% to $115.5 million during the first quarter. Ex-US sales increased 49% to $10.6 million ...
Shares of Medicines Co Under Pressure, Down 2.2% - Financial News Network Online
The Medicines Company develops products that improve specialized care. The Company markets Angiomax, an anticoagulant approved in the United States and other countries for use in patients undergoing coronary angioplasty procedures. Medicines Co (NASDAQ ...
Shares of Medicines Co Rank the Highest in Terms of Relative Performance in the Pharmaceuticals Industry (MDCO, QCOR, JNJ, PFE, SNY) - comcast.net
The Company markets Angiomax, an anticoagulant approved in the United States and other countries for use in patients undergoing coronary angioplasty procedures. Financial News Network Online (FNNO) is a leading provider of digital financial news content ...
Post-PCI Bleeds Drop with Shifts in Drug Strategy - MedPage Today
For example, the use of bivalirudin (Angiomax) increased from 17% to 30%, while employing heparin plus glycoprotein IIb/IIIa inhibitors (GPI) decreased from 41% to 28%, mostly driven by the use of bivalirudin-only in the UA/NSTEMI and elective PCI groups.
BUYINS.NET: TS, DLR, CPSI, MDCO, PIS, IKM Are Seasonally Ripe To Go Up In the Next Five Weeks - TMCnet
The company markets Angiomax for use in patients undergoing coronary angioplasty; and Cleviprex, an injectable emulsion for the reduction of blood pressure. Its developing products include Cangrelor, an antiplatelet agent, which is in phase III ...
